Большой и богатый Новартис очень надеялся — после серии неуспехов — на свое новое лекарство от сердечной недостаточности.

Возможно, побочные эфекты этого лекарства, поставят на нем крест.

Few drugs in Novartis’ ($NVS) pipeline loom larger than LCZ696, a heart failure med that has singlehandedly saved the pharma giant’s cardio drug development strategy from the embarrassing setback triggered by serelaxin’s big flop on the regulatory front. So now that a group of researchers are suggesting that the drug could—as in maybe, conceivably but certainly not for sure—be linked to accelerating Alzheimer’s, the new research is getting some very careful scrutiny.


Василий Власов